118 filings
Page 3 of 6
8-K
msglf9brauuh3gboass
7 Jun 22
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
f96fm2qf wf
20 May 22
Regulation FD Disclosure
4:12pm
8-K
tbyjuu5yv58lfj4
12 May 22
X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
anu3k75w 2du7a
17 Mar 22
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
8:23am
8-K
ruswow0yy 20
3 Mar 22
Entry into a Material Definitive Agreement
4:18pm
8-K
17nzgp4xcr z3
9 Feb 22
Entry into a Material Definitive Agreement
4:10pm
8-K/A
45hyflk83sskg76
26 Jan 22
Results of Operations and Financial Condition
7:56am
8-K
jkm4vxcgy 2s3c
25 Jan 22
Results of Operations and Financial Condition
5:13pm
8-K
yg5e yflm25fmqoxl3
14 Jan 22
Entry into a Material Definitive Agreement
5:01pm
8-K
ustc2xo9ior297sdrdif
14 Jan 22
Termination of a Material Definitive Agreement
4:10pm
8-K
6awj6v1g 22
13 Dec 21
Regulation FD Disclosure
5:24pm
8-K
sffexl
15 Nov 21
Regulation FD Disclosure
4:11pm
8-K
07znay
12 Nov 21
Departure of Directors or Certain Officers
4:05pm
8-K
43tjq2
5 Nov 21
Entry into a Material Definitive Agreement
5:27pm
8-K
22q 3g9gpbyeqkiy
4 Nov 21
Results of Operations and Financial Condition
9:01am
8-K
pq2or
19 Oct 21
Departure of Directors or Certain Officers
4:56pm
8-K
i68nyz9l8uw5905tcv0
10 Sep 21
Departure of Directors or Certain Officers
4:04pm
8-K
l2p0qti
6 Aug 21
Regulation FD Disclosure
4:05pm
8-K
v2q5rbcp 8r
3 Aug 21
X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter
8:12am
8-K
l32iradj
23 Jul 21
Other Events
4:04pm